Dr. Shaji Kumar on Novel Frontline Treatment Options in Multiple Myeloma

Shaji K. Kumar, MD
Published: Thursday, Jun 30, 2016



Shaji Kumar, MD, professor of Medicine, Mayo Clinic discusses going beyond bortezomib, lenalidomide, dexamethasone for newly diagnosed multiple myeloma.
 
In the phase III SWOG SO77 the bortezomib triplet showed improved survival over lenalidomide and dexamethasone alone, demonstrating a median progression-free survival (PFS) with the of 43 months versus 30 months with lenalidomide and dexamethasone alone (HR, 0.712; 96% CI, 0.560-0.906; one-sided P = .0018).
 
The focus should not be to improve on that combination, says Kumar. One option is to consider other proteasome inhibitor (PI)-based triplet therapies. The phase III ENDURANCE trial is comparing the carfilzomib-lenalidomide-dexamethasone combination to bortezomib-lenalidomide-dexamethasone combination in the frontline setting.
 
Using monoclonal antibodies like daratumumab and elotuzumab in combination with lenalidomide-dexamethasone is also an option, says Kumar. Panobinostat is also being investigated in frontline multiple myeloma.
 


Shaji Kumar, MD, professor of Medicine, Mayo Clinic discusses going beyond bortezomib, lenalidomide, dexamethasone for newly diagnosed multiple myeloma.
 
In the phase III SWOG SO77 the bortezomib triplet showed improved survival over lenalidomide and dexamethasone alone, demonstrating a median progression-free survival (PFS) with the of 43 months versus 30 months with lenalidomide and dexamethasone alone (HR, 0.712; 96% CI, 0.560-0.906; one-sided P = .0018).
 
The focus should not be to improve on that combination, says Kumar. One option is to consider other proteasome inhibitor (PI)-based triplet therapies. The phase III ENDURANCE trial is comparing the carfilzomib-lenalidomide-dexamethasone combination to bortezomib-lenalidomide-dexamethasone combination in the frontline setting.
 
Using monoclonal antibodies like daratumumab and elotuzumab in combination with lenalidomide-dexamethasone is also an option, says Kumar. Panobinostat is also being investigated in frontline multiple myeloma.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x